Liver Cancer

Cancer Epidemiology and Prevention

Volumn , Issue , 2009, Pages

  London, W Thomas ^a   Mcglynn, Katherine A ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer epidemiology; Cancer prevention; Cancer risk; Hcc; Hepatocellular carcinomas; Liver

Indexed keywords

EID: 84920471182     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780195149616.003.0039     Document Type: Chapter

References (448)

1. Adami HO, Chow WH, Nyren O, et al. 1996. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 88:1472-1477.
2. Adami HO, McLaughlin J, Ekbom A, et al. 1991. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 2:307-314.
3. Agundez JA, Olivera M, Ladero JM, et al. 1996. Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics 6:501-512.
4. Ahrendt SA, Nakeeb A, Pitt HA. 2001. Cholangiocarcinoma. Clin Liver Dis 5:191-218.
5. Aizawa Y, Shibamoto Y, Takagi I, Zeniya M, Toda G. 2000. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. Cancer 89:53-59.
6. Alter HJ, Seef LB. 2000. Recovery, persistence, and sequelae in hepatitis C infection: A perspective on long-term outcome. Semin Liv Dis 20:17-35.
7. Alter MJ. 1999. Hepatitis C virus infection in the United States. J Hepatol 31:S-1:88-91.
8. Andersson M, Carstensen B, Storm HH. 1995. Mortality and cancer incidence after cerebral arteriography with or without Thorotrast. Radiat Res 142:305-320.
9. Arase Y, Ikeda K, Murashima N, et al. 1997. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 79:1494-1500.
10. Asplin F, Carnaghan R. 1961. The toxicity of certain groundnut meals for poultry with special references to their effect on ducklings and chickens. Vet Rec 73:1215-1219.
11. Austin H, Delzell E, Grufferman S, et al. 1986. A case-control study of hepatocellular carcinoma and the hepatitis B virus, cigarette smoking and alcohol consumption. Cancer Res 46:962-966.
12. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. 1994. Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology 107:1103-1109.
13. Badawi AF, Michael MS. 1999. Risk factors for hepatocellular carcinoma in Egypt: The role of hepatitis-B viral infection and schistosomiasis. Anticancer Res 19:4565-4569.
14. Balkau B, Kahn HS, Courbon D, Eschwege E, Ducimetiere P. 2001. Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites: The Paris Prospective Study. Diabetes Care 24:583-849.
15. Bambha K, Kim WR, Talwalkar J, et al. 2003. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 125:1364-1369.
16. Basak R, Bhattacharya R, Chatterjee M. 2001. 1 alpha, 25-Dihydroxyvitamin D3 inhibits rat liver ultrastructural changes in diethylnitrosamine-initiated and phenobarbital promoted rat hepatocarcinogenesis. J Cell Biochem 81:357-367.
17. Bean P. 2002. The use of alternative medicine in the treatment of hepatitis C. Am Clin Lab 21:19-21.
18. Beasley RP. 1988. Hepatitis B virus, the major etiology of hepatocellular carcinoma. Cancer 61:1942-1956.
19. Beasley RP, Lin CC, Hwang LY, Chien CS. 1981. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22, 707 men in Taiwan. Lancet 2:1129-1133.
20. Bellentani S, Pozatto G, Saccoccio G, et al. 1999. Clinical course and risk factors of hepatitis C related liver disease in the general population: Report from the Dionysos study. Gut 44:874-880.
21. Bellentani S, Tiribelli C. 2001. The spectrum of liver disease in the general population: Lesson from the Dionysos study. J Hepatol 35:531-537.
22. Bellentani S, Tiribelli C, Saccoccio G, et al. 1994. Prevalence of chronic liver disease in the general population of northern Italy: The Dionysos Study. Hepatology 20:1442-1449.
23. Benhamou Y, Bochet M, Di Martino V, et al. 1999. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30:1054-1058.
24. Bergquist A, Ekbom A, Olsson R, et al. 2002. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 36:321-327.
25. Beutler E, Gelbart T, West C, et al. 1996. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 22:187-194.
26. Bian JC, Shen FM, Shen L, et al. 2000. Susceptibility to hepatocellular carcinoma associated with null genotypes of GSTM1 and GSTT1. World J Gastroenterol 6:228-230.
27. Billingsley GD, Walter MA, Hammond GL, Cox DW. 1993. Physical mapping of four serpin genes: alpha-1-antitrypsin, alpha-1-antichymotrypsin, corticosteroid-binding globulin, and protein C inhibitor, within a 280-kb region on chromosome 14q32.1. Am J Hum Genet 52:343-353.
28. Bjersing L, Andersson C, Lithner F. 1996. Hepatocellular carcinoma in patients from northern Sweden with acute intermittent porphyria: morphology and mutations. Cancer Epidemiol Biomarkers Prev 5:393-397.
29. Block TM, Mehta AS, Fimmel CJ, Jordan R. 2003. Molecular viral oncology of hepatocellular carcinoma. Oncogene 22:5093-5107.
30. Blount W. 1961. Turkey "X" disease. Turkeys (Journal of the British Turkey Federation) 9:55-58.
31. Boberg KM, Schrumpf E. 1998. Treatment of primary sclerosing cholangitis. In: Autoimmune Liver Diseases. 2nd ed. Krawitt EL, Wiesner RH, Nishioka M, eds. Amsterdam: Elsevier Science B.V, pp. 529-551.
32. Bonkovsky HL, Jawaid Q, Tortorelli K, et al. 1999. Non-alcoholic steatohepatitis and iron: Increased prevalence of mutations of the HFE gene in nonalcoholic steatohepatitis. J Hepatol 31:421-429.
33. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, et al. 1998. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 27:1661-1669.
34. Borecki IB, Rao DC, Le Mignon L, Yaouanq J, Simon M, Lalouel JM. 1989. Genetic hemochromatosis: Distribution analysis of six laboratory measures of iron metabolism. Am J Med Genet 34:435-441.
35. Bradbear RA, Bain C, Siskind V, et al. 1985. Cohort study of internal malignancy in genetic hemochromatosis and other chronic non-alcoholic liver diseases. J Natl Cancer Inst 75:81-84.
36. Braga C, La Vecchia C, Negri E, Franceschi S. 1997. Attributable risks of hepatocellular carcinoma in northern Italy. Eur J Cancer 33:629-634.
37. Brechot C, Degos F, Lugassy C, et al. 1985. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med 312:270-276.
38. Bressac B, Kew M, Wands J, Ozturk M. 1991. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350:429-431.
39. Brunt EM. 2000. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology. 31:241-246.
40. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. 1999. Nonalcoholic steatohepatitis: A proposal for grading and staging the histologic lesions. Am J Gastroenterol 94:2467-2474.
41. Bugianesi E, Leone N, Vanni E, et al. 2002. Expanding the natural history of nonalcoholic steatohepatitis: from crytogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123:134-140.
42. Bulaj ZJ, Griffen LM, Jorde LB, Edwards CQ, Kushner JP. 1996. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 355:1799-1805.
43. Byron D, Minuk GY. 1996. Clinical hepatology: Profile of an urban, hospital-based practice. Hepatology 24:813-815.
44. Cacoub P, Geffray L, Rosenthal E, et al. 2001. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis 32:1207-1214.
45. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. 1999. Cryptogenic cirrhosis; clinical characterization and risk factors for underlying disease. Hepatology 29:664-669.
46. Camaschella C, Roetto A, Cali A, et al. 2000. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 25:14-15.
47. Camma C, Giunta M, Andreone P, Craxi A. 2001. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach. J Hepatol 34:593-602.
48. Cardin R, D'Errico A, Fiorentino M, Cecchetto A, Naccarato R, Farinati F. 2002. Hepatocyte proliferation and apoptosis in relation to oxidative damage in alcohol-related liver disease. Alcohol 37:43-48.
49. CDC. 1998. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 47:1-33.
50. CDC. 2002. Geographic distribution of chronic HBV infection. Hepatitis B slide set (Internet).
51. CDC. 2003a. Prevention and control of infections with hepatitis viruses in correctional settings. MMWR 52:1-17.
52. CDC. 2003b. Global progress toward universal childhood hepatitis B vaccination, 2003. MMWR 52:868-869.
53. Chang MH, Chen CJ, Lai MS, et al. 1997. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 336:1855-1859.
54. Chapman RW. 1999. Risk factors for biliary tract carcinogenesis. Ann Oncol 10 (Suppl 4):308-311.
55. Chen CJ, Chen CW, Wu MM, Kuo TL. 1992. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 66:888-892.
56. Chen CJ, Chuang YC, Lin TM, Wu HY. 1985. Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: High-arsenic artesian well water and cancers. Cancer Res 45:5895-5899.
57. Chen CJ, Chuang YC, You SL, Lin TM, Wu HY. 1986. A retrospective study on malignant neoplasms of bladder, lung and liver in blackfoot disease endemic area in Taiwan. Br J Cancer 53:399-405.
58. Chen CJ, Kuo TL, Wu M-M. 1988a. Arsenic and cancers (letter). Lancet 1:414-415.
59. Chen CJ, Liang KY, Chang AS, et al. 1991. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology 13:398-406.
60. Chen CJ, Wang CJ. 1990. Ecological correlation between arsenic level in well water and age-adjusted mortality from malignant neoplasms. Cancer Res 50:5470-5474.
61. Chen CJ, Wu MM, Lee SS, Wang JD, Cheng SH, Wu HY. 1988b. Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis 8:452-460.
62. Chen CJ, Yu MW, Liaw Y-F, et al. 1996. Chronic hepatitis B carriers with null genotypes of glutathione s-transferase M1 and T1 polymorphisms who are exposed to aflatoxin are at increased risk of hepatocellular carcinoma. Am J Hum Genet 59:128-134.
63. Chen SY, Wang LY, Lunn RM, et al. 2002. Polycyclic aromatic hydrocarbon-DNA adducts in liver tissues of hepatocellular carcinoma patients and controls. Int J Cancer 99:14-21.
64. Chiesa R, Donato F, Tagger A, et al. 2000. Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis. Cancer Epidemiol Biomarkers Prev 9:213-216.
65. Chiou H-Y, Hsueh Y-M, Liaw K-F, et al. 1995. Incidence of internal cancers and ingested inorganic arsenic: A seven-year follow-up study in Taiwan. Cancer Res 55:1296-1300.
66. Choo QL, Kuo G, Weiner J, et al. 1989. Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science 244:359-362.
67. Chopra S, Bonis PA. 2003. Liver transplantation for hepatitis C virus infection. In: UpToDate Online. Rose BD, ed. Wellesley, MA: UptoDate.
68. Chou YH, Chiou HJ, Tiu CM, et al. 2003. Duplex doppler ultrasound of hepatic schistosomiasis japonica: A study of 47 patients. Am J Trop Med Hyg 68:18-23.
69. Christopherson W, Mays E, Barrows G. 1980. Liver tumours in young women. In: Progress in Surgical Pathology. Vol. 2. Fenoglio CM, Wolff M, eds. New York: Masson Publishing UK, pp. 187-205.
70. Chuang SE, Kuo ML, Hsu CH, et al. 2000. Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis. Carcinogenesis 21:331-335.
71. Colditz GA for the Nurses' Health Study Research Group. 1994. Oral contraceptive use and mortality during 12 years of follow-up: The Nurses' Health Study. Ann Intern Med 120:821-826.
72. Cole P, Macmahon B, Brown JB. 1976. Oestrogen profiles of parous and nulliparous women. Lancet 2:596-599.
73. Colin JF, Cazals-Hatem D, Loriot MA, et al. 1999. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 29:1306-1310.
74. Collaborative MILTS Project Team. 1997. Oral contraceptives and liver cancer. Contraception 56:275-284.
75. Colli A, Fraquelli M, Andreoletti M, et al. 2003. Severe liver fibrosis or cirrhosis: Accuracy of US for detection-analysis of 300 cases. Radiology 227:89-94.
76. Colombo M. 1998. The role of hepatitis C virus in hepatocellular carcinoma. Recent Results Cancer Res 154:337-344.
77. Colombo M, De Franchis R, Del Ninno E, et al. 1991. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 325:675-680.
78. Corrao G, Arico S. 1998. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 27:914-919.
79. Corrao G, Arico S, Zambon A, Torchio P, Di Orio F. 1997. Female sex and the risk of liver cirrhosis. Collaborative Groups for the Study of Liver Diseases in Italy. Scand J Gastroenterol 32:1174-1180.
80. Corrao G, Bagnardi V, Zambon A, Arico S. 1999. Exploring the dose-response relationship between alcohol consumption and the risk of several alcohol-related conditions: A meta-analysis. Addition 94:1551-1573.
81. Cotrim HP, Parana R, Braga E, Lyra L. 2000. Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history? Am J Gastroenterol 95:3018-3019.
82. Creech J, Johnson M. 1974. Angiosarcoma of the liver in the manufacture of PVC. J Occup Med 13:150-151.
83. Curley SA, Barnett CC, Abdalla EK. 2003. Liver transplantation of hepatocellular carcinoma. In: UpToDate Online. Rose BD, ed. Wellesley, MA, UptoDate.
84. Darby SC, Ewart DW, Giangrande PL. 1997. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 350:1425-1431.
85. Darwish MA, Raouf TA, Rushdy P, Constantine NT, Rao MR, Edelman R. 1993. Risk factors associated with a high seroprevalence of hepatitis C virus infection in Egyptian blood donors. Am J Trop Med Hyg 49:440-447.
86. Datz C, Haas T, Rinner H, Sandhofer F, Patsch W, Paulweber B. 1998. Heterozygosity for the C292Y mutation in the hemochromatosis gene is associated with increased serum iron, transferrin saturation, and hemoglobin in young women: A protective role against iron deficiency? Clin Chem 44:2429-2432.
87. De Groen PC, Gores GJ, Larusso NF, Gunderson LL, Nagorney DM. 1999. Biliary tract cancers. N Engl J Med. 341:1368-1378.
88. De Maria N, Manno M, Villa E. 2002. Sex hormones and liver cancer. Mol Cell Endocrinol 193:59-63.
89. Deng Z, Wei Y, Ma Y. 2001. Glutathione-S-transferase M1 genotype in patients with hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 23:477-479.
90. Deugnier YM, Guyader D, Crantock L, et al. 1993. Primary liver cancer in genetic hemochromatosis: A clinical, pathological and pathogenetic study of 54 cases. Gastroenterology 104:228-234.
91. Di Bisceglie AM, Goodman ZD, Ishak KG, et al. 1991. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology. 14:969-974.
92. Donato F, Gelatti U, Tagger A. 2001. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: A case-control study in Italy. Cancer Causes Control 12:959-964.
93. Donato F, Tagger A, Gelatti U, et al. 2002. Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 155:323-331.
94. Dos Santos Silva I, Jones M, Malveiro F, Swerdlow A. 1999. Mortality in the Portuguese Thorotrast study. Radiat Res 152:S88-S93.
95. Duck BW, Carter JT, Coombes EJ. 1975. Mortality study of workers in a polyvinyl-chloride production plant. Lancet 13:1197-1199.
96. Dunn MA. 2003. Parasitic diseases. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff's Diseases of the Liver. Philadelphia: Lippincott Williams & Wilkins, pp. 1509-1527.
97. Edmondson HA. 1958. In: Tumors of the Liver and Intrahepatic Bile Ducts. Washington: Armed Forces Institute of Pathology, pp. 32-33.
98. Edmondson HA, Henderson B, Benton B. 1976. Liver cell adenomas associated with the use of the oral contraceptive. N Engl J Med 294:470-472.
99. Edmondson HA, Steiner PE. 1954. Primary carcinoma of the liver. A study of 100 cases among 48,000 autopsies. Cancer 7:462-503.
100. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. 2003. The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update. Ann Intern Med 139:817-823.
101. El-Serag HB, Hampel H, Yeh C, Rabeneck L. 2002. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 36:1439-1445.
102. El-Serag HB, Mason AC. 1999. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745-750.
103. El-Serag HB, Richardson PA, Everhart JE. 2001. The role of diabetes in hepatocellular carcinoma: A case-control study among United States veterans. Am J Gastroenterol 96:2462-2467.
104. El-Zayadi AR, Abaza H, Shawky S, Mohamed MK, Selim OE, Badran HM. 2001. Prevalence and epidemiological features of hepatocellular carcinoma in Egypt-a single center experience. Hepatol Res 19:170-179.
105. Eriksson S, Carlson J, Velez R. 1986. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med 314:736-739.
106. Evans AA, Chen G, Ross EA, et al. 2002. Eight-year follow-up of the 90,000-person Haimen City Cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev 11:369-376.
107. Evans DM, Williams WJ, Kung IT. 1983. Angiosarcoma and hepatocellular carcinoma in vinyl chloride workers. Histopathology 7:377-388.
108. Falk H, Caldwell GG, Ishak KG, Thomas LB, Popper H. 1981. Arsenic-related hepatic angiosarcoma. Am J Ind Med 2:43-50.
109. Farber E, Cameron R. 1980. The sequential analysis of cancer development. Adv in Cancer Research 31:125-226.
110. Fargion S, Fracanzani AL, Piperno A, et al. 1994. Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis. Hepatology 20:1426-1431.
111. Farrell GC. 2003. Non-alcoholic steatohepatitis: what is it and why is it important in the Asia-Pacific region? J Gastroenterol Hepatol 18:124-138.
112. Fausto N, Campbell JS. 2003. The role of hepatocytes and oval cells in liver regeneration and repopulation. Mechanisms of Development 120:117-130.
113. Feder JN, Gnirke A, Thomas W, et al. 1996. A novel MHC class-I like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13:399-408.
114. Feder JN, Tsuchihashi Z, Irrinki A, et al. 1997. The hemochromatosis founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell surface expression. J Biol Chem 272:14025-14028.
115. Feitelson MA, Sun B, Satiroglu Tufan NL, et al. 2002. Genetic mechanisms of hepatocarcinogenesis. Oncogene 21:2593-2604.
116. Ferlay J, Bray J, Pisani P, Parkin DM. 2001. Globocan 2000-cancer incidence, mortality and prevalence worldwide. Lyon: IARCPress.
117. Figueras J, Jaurrieta E, Valls C, et al. 1997. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: A comparative study. Hepatology 25:1485-1489.
118. Filippazzo M, Aragona E, Cottone M, et al. 1985. Assessment of some risk factors for hepatocellular carcinoma: A case-control study. State Med 4:345-351.
119. Flora KD, Berk B. 2002. Hepatocellular adenoma. In: Patel T, Talavera F, Achord JL, Mechaber AJ, Katz J, eds. eMedicine, Gastroenterology (Internet).
120. Fontana RJ, Lok AS. 2003. Liver transplantation for chronic hepatitis B infection. In: UpToDate Online. Rose BD, ed. Wellesley, MA: UpToDate.
121. Forman D, Bennett B, Stafford J, Doll R. 1985. Exposure to vinyl chloride and angiosarcoma of the liver: A report of the register of cases. Br J Ind Med 42:750-753.
122. Forman D, Vincent TJ, Doll R. 1986. Cancer of the liver and the use of oral contraceptives. Br Med J 292:1357-1361.
123. Frank C, Mohamed MK, Strickland GT, et al. 2000. The role of parenteral antischistosomal therapy in the spread of hepatitis C in Egypt. Lancet 355:887-891.
124. Frezza M, Di Padova C, Pozzato G, Perin M, Baraona E, Lieber CS. 1990. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med 322:95-99.
125. Frisch M, Biggar RJ, Engels EA, Goedert JJ; Aids-Cancer Match Registry Study Group. 2001. Association of cancer with AIDS-related immunosuppression in adults. JAMA 285:1736-1745.
126. Fukuda K, Shibata A, Hirohata I, Tanikawa K, Yamaguchi G, Ishii M. 1993. A hospital based case-control study on hepatocellular carcinoma in Fukuoka and Saga prefectures, Northern Kyushu, Japan. Jpn J Cancer Res 84:708-714.
127. Gaiani S, Gramantieri L, Venturoli N, et al. 1997. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol 27:979-985.
128. Ganne-Carrie N, Christidis C, Chastang C, et al. 2000. Liver iron is predictive of death in alcoholic cirrhosis: A multivariate study of 229 consecutive patients with alcoholic and/or hepatitis C virus cirrhosis: A prospective follow-up study. Gut 46:277-282.
129. Gebo KA, Chander G, Jenckes MW, et al. 2002. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: A systematic review. Hepatology 36:S84-92.
130. George DK, Goldwurm S, Macdonald GA, et al. 1998. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 114:311-318.
131. Ghaffar YA, Fattah SA, Kamel M, Badr RM, Mahomed FF, Strickland GT. 1991. The impact of endemic schistosomiasis on acute viral hepatitis. Am J Trop Med Hyg 45:743-750.
132. Gilson RJ, Hawkins AE, Beecham MR, et al. 1997. Interactions between HIV and hepatitis B virus in homosexual men: Effects on the natural history of infection. AIDS 11:597-606.
133. Ginseng-HCC Chemopreventive Study Osaka Group. 2001. Study on chemoprevention of hepatocellular carcinoma by ginseng: An introduction to the protocol. J Korean Med Sci 16 Suppl:S70-S74.
134. Goedert JJ, Hatzakis A, Sherman KE, Eyster ME, Multicenter Hemophilia Cohort Study. 2001. Lack of association of hepatitis C virus load and genotype with risk of end-stage liver disease in patients with human immunodeficiency virus coinfection. J Infect Dis 184:1202-1205.
135. Goh J, Callagy G, McEntee G, O'Keane J, Bomford A, Crowe J. 1999. Hepatocellular carcinoma arising in the absence of cirrhosis in genetic haemochromatosis: Three case reports and a review of the literature. Eur J Gastroenterol Hepatol 11:159-191.
136. Gong Y, Han C, Chen J. 2000. Effect of tea polyphenols and tea pigments on the inhibition of precancerous liver lesions in rats. Nutr Cancer 38:81-86.
137. Gong YY, Egal S, Hounsa A, et al. 2003. Determinants of aflatoxin exposure in young children from Benin and Togo, West Africa: The critical role of weaning. Int J Epidemiol 32:556-562.
138. Gonzalez SA, Talal AH. 2003. Hepatitis C virus in human immunodeficiency virus-infected individuals: An emerging comorbidity with significant implications. Gut 47:845-851.
139. Goodman MT, Moriwaki H, Vaeth M, Akiba S, Hayabuchi H, Mabuchi K. 1995. Prospective cohort study of risk factors for primary liver cancer in Hiroshima and Nagasaki, Japan. Epidemiology 6:36-41.
140. Gordeuk, V, Mukiibi J, Hasstedt SJ, et al. 1992. Iron overload in Africa: Interaction between a gene and dietary iron content. N Engl J Med 326:95-100.
141. Gordeuk VR, McLaren CE, MacPhail AP, Deichsel G, Bothwell TH. 1996. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachan's 1929 thesis revisited. Blood 87:3470-3476.
142. Guyton KZ, Kensler TW. 2002. Prevention of liver cancer. Curr Oncol Rep 4:464-470.
143. Hadziyannis S, Tabor E, Kaklamani E, et al. 1995. A case-control study of hepatitis B and C virus infections in the etiology of hepatocellular carcinoma. Int J Cancer 60:627-631.
144. Halim AB, Gary RF, Dash S, Gerber MA. 1999. Effect of schistosomiasis and hepatitis on liver disease. Am J Trop Med Hyg 60:915-920.
145. Halver J. 1965. Hepatomas in fish. In: Burdette W, eds. Primary Hepatoma. Utah: Utah Press, pp. 103-112.
146. Hann HL, Kim C, London WT, et al. 1982. Hepatitis B virus and primary hepatocellular carcinoma: Family studies in Korea. Int J Cancer 30:47-51.
147. Hannaford PC, Kay CR, Vessey MP, Painter R, Mant J. 1997. Combined oral contraceptives and liver disease. Contraception 55:145-151.
148. Hanson EH, Imperatore G, Burke W. 2001. HFE gene and hereditary hemochromatosis: A HuGE review. Am J Epidemiol 154:193-206.
149. Hardell L, Bengtsson NO, Jonsson U, Eriksson S, Larsson LG. 1984. Aetiological aspects on primary liver cancer with special regard to alcohol, organic solvents and acute intermittent porphyria-an epidemiological investigation. Br J Cancer 50:389-397.
150. Harnois DM, Gores GJ, Ludwig J, Steers JL, Larusso NF, Wiesner RH. 1997. Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? J Hepatol 27:512-516.
151. Hassan MM, Hwang L-Y, Hatten CJ, et al. 2002. Risk factors for hepatocellular carcinoma; synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 36:1206-1213.
152. Hassan MM, Zaghloul AS, El-Serag HB, et al. 2001. The role of hepatitis C in hepatocellular carcinoma. A case-control study among Egyptian patients. J Clin Gastroenterol 33:123-126.
153. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. 1994. Improvements of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 89:986-988.
154. Hayashi K, Kumada T, Nakano S, et al. 2002. Incidence of hepatocellular carcinoma in chronic hepatitis C after interferon therapy. Hepatogastroenterology 49:508-512.
155. Heilbrun LK, Nomura A, Stemmermann GN. 1986. Black tea consumption and cancer risk: A prospective study. Br J Cancer 54:677-683.
156. Henderson BE, Preston-Martin S, Edmondson HA, Peters RL, Pike MC. 1983. Hepatocellular carcinoma and oral contraceptives. Br J Cancer 48:437-440.
157. Heyward WL, Lanier AP, McMahon BJ, et al. 1985. Early detection of primary hepatocellular carcinoma. Screening for primary hepatocellular carcinoma among persons infected with hepatitis B virus. JAMA 254:3052-3054.
158. Hift RF, Corrigall AV, Hancock V, Kannemeyer J, Kirsch RE, Meissner PN. 2002. Porphyria cutanea tarda: the etiological importance of mutations in the HFE gene and viral infection is population-dependent. Cell Mol Biol 48:853-859.
159. Higginson J, Grobellar BG, Walker ARP. 1957. Hepatic fibrosis and cirrhosis in man in relation to malnutrition. Am J Pathol 33:29-54.
160. Hirayama T. 1989. A large-scale cohort study on risk factors for primary liver cancer, with special reference to the role of cigarette smoking. Cancer Chemother Pharmacol 23:S114-S117.
161. Hirayama T. 1990. Life-Style and Mortality: A Large-Scale Census-Based Cohort Study in Japan. Vol. 6. Contributions to Epidemiology and Biostatistics. Basel, Karger.
162. Hopenhayn-Rich C, Biggs ML, Smith AM. 1988. Lung and kidney cancer mortality associated with arsenic in drinking water in Cordoba, Argentina. Int J Epidemiol 27:561-569.
163. Hsieh LL, Huang RC, Yu MW, Chen CJ, Liaw YF. 1996. L-myc, GSTM1 genetic polymorphism and hepatocellular carcinoma risk among chronic hepatitis B carriers. Cancer Lett 103:171-176.
164. Hsing AW, Gwo W, Chen J, Stone BJ, Blot WJ, Fraumeni JF, Jr. 1991. Correlates of liver cancer mortality in China. Int J Epidemiol 20:54-59.
165. Hsing AW, Hoover RN, McLaughlin JK, et al. 1992a. Oral contraceptives and primary liver cancer among young women. Cancer Causes Control 3:43-48.
166. Hsing AW, McLaughlin JK, Hoover RN, Co Chien HT, Blot WJ, Fraumeni JF, Jr. 1992b. Parity and primary liver cancer among young women. J Natl Cancer Inst 84:1118-1119.
167. Hsing AW, McLaughlin JK, Hrubec Z, et al. 1990. Cigarette smoking and liver cancer among US veterans. Cancer Causes Control 1:217-221.
168. Hsu IC, Metcalf RA, Sun T, et al. 1991. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350:427-428.
169. Hu KQ. 2002. Rationale and feasibility of chemoprevention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J Lab Clin Med 139:234-243.
170. Huang YS, Chern HD, Wu JC, et al. 2003. Polymorphism of the Nacetyltransferase 2 gene, red meat intake, and the susceptibility of hepatocellular carcinoma. Am J Gastroenterol 98:1417-1422.
171. IARC Monographs. 1987a. Overall evaluations of carcinogenicity: An updating of IARC monographs volumes 1-42. Suppl 7. Lyon: IARCPress, pp. 83-87.
172. IARC Monographs. 1987b. Overall evaluations of carcinogenicity: An updating of IARC monographs volumes 1-42. Suppl 7. Lyon: IARCPress, pp. 96-98.
173. IARC Monographs. 1988. Alcohol drinking. Vol. 44. Lyon: IARCPress, pp. 255-259.
174. IARC Monographs. 1994a. Hepatitis viruses. Vol. 59. Lyon: IARCPress, pp. 72-97.
175. IARC Monographs. 1994b. Schistosomes, liver flukes and helicobacter pylori. Vol. 61. Lyon: IARCPress, pp. 45-119.
176. IARC Monographs. 1994c. Schistosomes, liver flukes and helicobacter pylori. Vol. 61. Lyon: IARCPress, pp. 121-175.
177. IARC Monographs. 1999. Hormonal contraception and post-menopausal hormonal therapy. Vol. 72. Lyon: IARCPress, pp. 293.
178. Iida F, Iida R, Kamijo H, et al. 1999. Chronic Japanese schistosomiasis and hepatocellular carcinoma: Ten years of follow-up in Tamanashi Prefecture, Japan. Bull World Health Organ 77:573-581.
179. Ijima T, Saitoh N, Nobotumo K, et al. 1984. A prospective cohort study of hepatitis B surface antigen carriers in a working population. Gann 75:571-573.
180. Ikeda K, Saitoh S, Kobayashi M, et al. 2001. Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: A pilot study. J Gastroenterol Hepatol 16:406-415.
181. Ikeda K, Saitoh S, Koida I, et al. 1993. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 18:47-53.
182. Ikeda K, Saitoh S, Suzuki Y, et al. 1998. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: A prospective observation of 2215 patients. J Hepatol 28:930-938.
183. Imbert-Bismut F, Ratziu V, Pieroni L, et al. 2001. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet. 357:1069-1075.
184. Ishak KG. 1987. Malignant mesenchymal tumors of the liver. In: Okuda K, Ishak KG, eds. Neoplastic Diseases of the Liver. Berlin: Springer-Verlag, pp. 159-176.
185. Ishii A, Matsuoka H, Aji T, et al. 1994. Parasite infection and cancer: With special emphasis on Schistosoma japonicum infections (Trematoda). A review. Mutat Res 305:273-281.
186. Jazwinska EC, Cullen LM, Busfield F, et al. 1996. Haemochromatosis and HLA-H. Nat Genet 14:249-251.
187. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. 2003. Cancer Statistics, 2003. CA Cancer J Clin 53:5-26.
188. Jones J. 2001. New alcohol strategy being developed for England. BMJ 322:636.
189. Jouanolle AM, Gandon G, Jezequel P, et al. 1996. Haemochromatosis and HLA H. Nat Genet 14:251-252.
190. Kakizaki S, Takagi H, Fukusato T, et al. 2001. Effect of alpha-tocopherol on hepatocarcinogenesis in transforming growth factor-alpha (TGF-alpha) transgenic mice treated with diethylnitrosamine. Int J Vitam Nutr Res 71:261-267.
191. Kalk H. 1960. The relationship between fatty liver and diabetes mellitus. Ger Med Mon 5:81-84.
192. Kane MA. 2003. Global control of primary hepatocellular carcinoma with hepatitis B vaccine: The contributions of research in Taiwan. Cancer Epidemiol Biomarkers Prev 12:2-3.
193. Kasahara A, Hayashi N, Mochizuki K, et al. 1998. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 27:1394-1402.
194. Kato J, Kobune M, Nakamura T, et al. 2001. Normalization of elevated hepatic 8-hydroxy-2'-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 61:8697-8702.
195. Kaul A. 1995. Biokinetic models and data. In: van Kaick G, Karaoglou A, Kellerer AM, eds. Health Effects of Internally Deposited Radionuclides: Emphasis on Radium and Thorium. Singapore: World Scientific Publishing Co., pp. 53-68.
196. Kenny-Walsh E for the Irish Hepatology Research Group. 1999. Clinical outcomes after hepatitis infection from contaminated anti-globulin. N Engl J Med 340:1228-1233.
197. Ketcham AS, Wexler H, Mantel N. 1963. Effect of alcohol in mouse neoplasia. Cancer Res 23:667-670.
198. Kew M, Di Bisceclie A, Paterson A, et al. 1985. Smoking as a risk factor in hepatocellular carcinoma. A case-control study in southern African blacks. Cancer 56:2315-2317.
199. Kew MC, Song E, Mohammed A, Hodkinson J. 1990. Contraceptive steroids as a risk factor for hepatocellular carcinoma: A case-control study in South African black women. Hepatology 11:298-302.
200. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. 2002. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 37:806-813.
201. Kielhorn J, Melber C, Wahnschaffe U, Aitto A, Mangelsdorf I. 2000. Vinyl chloride: still a cause for concern. Environ Health Perspect 108:579-588.
202. Kiyosawa K, Sodeyama T, Tanaka E, et al. 1990. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 12:671-675.
203. Klatskin G. 1977. Hepatic tumors-possible relationship to use of oral contraceptives. Gastroenterology 73:386-394.
204. Klaunig JE. 1992. Chemopreventive effects of green tea components on hepatic carcinogenesis. Prev Med 21:510-519.
205. Kobayashi M, Ikeda K, Saitoh S, et al. 2000. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer 88:2471-2477.
206. Kojiro M, Nakashima T. 1987. Pathology of hepatocellular carcinoma. In: Okuda K, Ishak KG, eds. Neoplastic Diseases of the Liver. Berlin: Springer-Verlag, pp. 81-104.
207. Kono S, Ikeda M, Tokudome S, et al. 1987. Cigarette smoking, alcohol and cancer mortality: A cohort study of male Japanese physicians. Jpn J Cancer Res 78:1323-1328.
208. Koretz RL, Abbey H, Coleman E, Gitnick G. 1993. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade. Ann Intern Med 19:110-115.
209. Kosaka A, Takahashi H, Yajima Y, et al. 1996. Hepatocellular carcinoma associated with anabolic steroid therapy: Report of a case and review of the Japanese literature. J Gastroenterol 31:450-454.
210. Koskinen SV, Reunanen AR, Martelin TP, Valkonen T. 1998. Mortality in a large population-based cohort of patients with drug-treated diabetes mellitus. Am J Public Health 88:765-770.
211. Kumada H. 2002. Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma. Oncology 62 Suppl 1:94-100.
212. Kuper H, Tzonou A, Kaklamani E, et al. 2000a. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 85:498-502.
213. Kuper H, Tzonou A, Lagiou P, et al. 2000b. Diet and hepatocellular carcinoma: A case-control study in Greece. Nutr Cancer 38:6-12.
214. La Vecchia C, Negri E, Decarli A, D'Avanzo B, Franceschi S. 1988. Risk factors for hepatocellular carcinoma in northern Italy. Int J Cancer 42:872-876.
215. La Vecchia C, Negri E, Franceschi S, D'Avanzo B. 1992. Reproductive factors and the risk of hepatocellular carcinoma in women. Int J Cancer 52:351-354.
216. La Vecchia C, Negri E, Franceschi S, Parazzini F. 1993. Long-term impact of reproductive factors on cancer risk. Int J Cancer 53:215-219.
217. Ladero JM, Agundez JA, Rodriguez-Lescure A, Diaz-Rubio M, Benitez J. 1996. RsaI polymorphism at the cytochrome P4502E1 locus and risk of hepatocellular carcinoma. Gut 39:330-333.
218. Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulos D, Adami H-O. 2000. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 92:1096-1099.
219. Lam KC, Yu MC, Leung JW, Henderson BE. 1982. Hepatitis B virus and cigarette smoking: Risk factors for hepatocellular carcinoma in Hong Kong. Cancer Res 42:5246-5248.
220. Lambe M, Trichopoulos D, Hsieh CC, Ekbom A, Pavia M. 1993. Parity and hepatocellular carcinoma. A population-based study in Sweden. Int J Cancer 55:745-747.
221. Lander JJ, Stanley RJ, Sumner HW, Boswell DC, Aach RD. 1975. Angiosarcoma of the liver associated with Fowler's solution (potassium arsenite). Gastroenterology 68:1582-1586.
222. Larouze B, Saimot G, Lustbader ED, et al. 1976. Host responses to hepatitisB infection in patients with primary hepatic carcinoma and their families. A case/control study in Senegal, West Africa. Lancet 2:534-538.
223. Lee CL, Hsieh KS, Ko YC. 2003. Trends in the incidence of hepatocellular carcinoma in boys and girls in Taiwan after large-scale hepatitis B vaccination. Cancer Epidemiol Biomarkers Prev 12:57-59.
224. Lee CL, Ko YC. 1997. Hepatitis B vaccination and hepatocellular carcinoma in Taiwan. Pediatrics 99:351-353.
225. Lee HS, Yoon JH, Kamimura S, Iwata K, Watanabe H, Kim CY. 1997. Lack of association of cytochrome P450 2E1 genetic polymorphisms with the risk of human hepatocellular carcinoma. Int J Cancer 71:737-740.
226. Lelbach WK. 1996. A 25-year follow-up study of heavily exposed vinyl chloride workers in Germany. Am J Ind Med 29:446-458.
227. Lewis DR, Southwick JW, Ouellet-Hellstrom R, Rench J, Calderon RL. 1999. Drinking water arsenic in Utah: A cohot mortality study. Environ Health Perspect 107:359-365.
228. Lin L, Yang F, Ye Z, et al. 1991. Case-control study of cigarette smoking and primary hepatoma in an aflatoxin-endemic region of China: A protective effect. Pharmacogenetics 1:79-85.
229. Lindor KD, Larusso NF. 2003. Primary sclerosing cholangitis. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff's Diseases of the Liver. Philadelphia: Lippincott Williams & Wilkings, pp. 673-684.
230. Linet MS, Gridley G, Nyren O, et al. 1999. Primary liver cancer, other malignancies, and mortality risks following porphyria: A cohort study in Denmark and Sweden. Am J Epidemiol 149:1010-1015.
231. Lipshutz GS, Brennan TV, Warren RS. 2002. Thorotrast-induced liver neoplasia: A collective review. J Am Coll Surg 195:713-718.
232. Liver Cancer Study Group of Japan. 1984. Primary liver cancer in Japan. Cancer 54:1747-1755.
233. Llovet JM, Burroughs A, Bruix J. 2003. Hepatocellular carcinoma. Lancet 362:1907-1917.
234. Lok AS, McMahon BJ; Practice Guidelines Committee, American Association for the Study of Liver Diseases. 2001. Chronic hepatitis B. Hepatology 34:1225-1241.
235. Lu JN, Chen CJ. 1991. Prevalence of hepatitis B surface antigen carrier status among residents in the endemic area of chronic arsenicism in Taiwan. Anticancer Res 11:229-234.
236. Lu SN, Lin TM, Chen CJ, et al. 1988. A case-control study of primary hepatocellular carcinoma in Taiwan. Cancer 62:2051-2055.
237. Ludwig J, McGill DB, Lindor KD. 1997. Review: Nonalcoholic steatohepatitis. J Gastroenterol Hepatol 12:398-403.
238. Ludwig J, Viggiano TR, McGill DB, Ott BJ. 1980. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55:434-438.
239. Lundvall O, Weinfeld A. 1968. Studies of the clinical and metabolic effects of phlebotomy treatment in porphyria cutanea tarda. Acta Med Scand 184:191-199.
240. Lyra LG, Reboucas G, Andrade ZA. 1976. Hepatitis B surface antigen carrier state in hepatosplenic schistosomiasis. Gastroenterology 71:641-645.
241. MacMahon HE, Murphy AS, Bates MI. 1947. Endothelial-cell sarcoma of the liver following Thorotrast injections. Am J Path 23:585-611.
242. Madwar MA, El Tahawy M, Strickand GT. 1989. The relationship between uncomplicated schistosomiasis and hepatitis B infection. Trans R Soc Trop Med Hyg 83:233-236.
243. Mahoney FJ, Kane MA. 1999. Hepatitis B vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccine. ed 3. Philadelphia: WB Saunders, pp. 158-182.
244. Mandishona E, MacPhail AP, Gordeuk VR, et al. 1998. Dietary iron overload as a risk factor for hepatocellular carcinoma in Black Africans. Hepatology 27:1563-1566.
245. Marinier E, Barrois V, Larouze B, et al. 1985. Lack of perinatal transmission of hepatitis B virus in Senegal, West Africa. J Pediatr 106:843-849.
246. Marion PL, Van Davelaar MJ, Knights SS, et al. 1986. Hepatocellular carcinoma in ground squirrels persistently infected with ground squirrel hepatitis virus. Proc Natl Acad Sci USA 83:4543-4546.
247. Maruyama S, Nagasue N, Dhar DK, et al. 2001. Preventive effect of FK143, a 5a-reductase inhibitor, on chemical hepatocarcinogenesis in rats. Clin Cancer Res 7:2096-2104.
248. Mason AL, Lau JY, Hoang N, et al. 1999. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29:328-333.
249. Mattsson L, Sonnerborg A, Weiland O. 1993. Outcome of acute symptomatic non-A, non-B hepatitis: A 13-year follow-up study of hepatitis C virus markers. Liver 13:274-278.
250. Mays E, Christopherson W. 1984. Hepatic tumors induced by sex steroids. Semin Liver Dis 4:147-157.
251. McCoy GD, Hecht SS, Katayama S, Wynder EL. 1981. Differential effect of chronic ethanol consumption on the carcinogenicity of N-nitrosopyrrolidine and N'-nitrosonornicotine in male Syrian golden hamsters. Cancer Res 41:2849-2854.
252. McGlynn KA, Hunter K, Levoyer T, et al. 2003. Susceptibility to aflatoxin B1-related primary hepatocellular carcinoma in mice and humans. Cancer Res 63:4594-4601.
253. McGlynn KA, Rosvold EA, Lustbader ED, et al. 1995. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the detoxification of aflatoxin B1. Proc Natl Acad Sci USA 92:2384-2387.
254. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF, Jr. 2001. International trends and patterns of primary liver cancer. Int J Cancer 94:290-296.
255. McLaughlin JK, Lipworth L. 1999. A critical review of the epidemiologic literature on health effects of occupational exposure to vinyl chloride. J Epidemiol Biostat 4:253-275.
256. McNamara L, MacPhail AP, Gordeuk VR, Hasstedt SJ, Rouault T. 1998. Is there a link between African iron overload and the described mutations of the hereditary hemochromatosis gene? Br J Haematol 102:1176-1178.
257. Mettlin C, Natarajan N. 1981. Studies on the role of oral contraceptive use in the etiology of benign and malignant liver tumors. J Surg Oncol 18:73-85.
258. Ming L, Thorgeirsson SS, Gail MH, et al. 2002. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 36:1214-1220.
259. Miyakawa H, Izumi N, Marumo F, Sato C. 1996. Roles of alcohol, hepatitis virus infection, and gender in the development of hepatocellular carcinoma in patients with liver cirrhosis. Alcohol Clin Exp Res 20 (1S):91A-94A.
260. Mizoue T, Totui N, Nishisaka K, et al. 2000. Prospective study on the relation of cigarette smoking with cancer of the liver and stomach in an endemic region. Int J Epidemiol 29:232-237.
261. Monson RR, Peters JM, Johnson MN. 1974. Proportional mortality among vinyl-chloride workers. Lancet 2:397-398.
262. Morcos M, Dubois S, Bralet MP, Belghiti J, Degott C, Terris B. 2001. Primary liver cancer in genetic hemochromatosis reveals a broad histologic spectrum. Am J Clin Pathol 116:738-743.
263. Mori M, Hara M, Wada I, et al. 2000. Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan. Am J Epidemiol 151:131-139.
264. Mori T, Fukutomi K, Kato Y, et al. 1999a. 1998 results of the first series of follow-up studies on Japanese Thorotrast patients and their relationships to an autopsy series. Radiat Res 152:S72-S80.
265. Mori T, Kido C, Fukutomi K, et al. 1999b. Summary of entire Japanese Thorotrast follow-up study: Updated 1998. Radiat Res 152:S84-S87.
266. Moyo VM, Makunike R, Gangaidzo IT, et al. 1998. African iron overload and hepatocellular carcinoma. Eur J Haematol 60:28-34.
267. Mu LN, Zhou XF, Ding BG, et al. 2003. A case-control study on drinking green tea and decreasing risk of cancers in the alimentary canal among cigarette smokers and alcohol drinkers. Zhonghua Liu Xing Bing Xue Za Zhi 24:192-195.
268. Mucci LA, Kuper HE, Tamimi R, Lagiou P, Spanos E, Trichopoulos D. 2001. Age at menarche and age at menopause in relation to hepatocellular carcinoma in women. BJOG 108:291-294.
269. Mukaiya M, Nishi M, Miyake H, et al. 1998. Chronic liver diseases for the risk of hepatocellular carcinoma: A casecontrol study in Japan. Etiologic association of alcohol consumption, cigarette smoking and the development of chronic liver diseases. Hepatogastroenterology 45:2328-2332.
270. Nagano K, Fukuda Y, Nakano I, et al. 2000. A case of the development of two hepatocellular carcinomas and a cholangiocarcinoma with cirrhosis after elimination of serum hepatitis C virus RNA with interferon therapy. Hepatogastroenterology 47:1436-1438.
271. National Academy of Sciences. 1988. Health risks of radon and other internally deposited alpha-emitters. Washington, DC: National Academy Press, Bier IV Report.
272. Nayak NC, Dhar A, Sachdeva R. 1977. Association of human hepatocellular carcinoma and cirrhosis with hepatitis B surface and core antigens in the liver. Int J Cancer 20:643-654.
273. Nelson RL, Davis FG, Persky V, Becker E. 1995. Risk of neoplastic and other disease among people with heterozygosity for hereditary hemochromatosis. Cancer 76:875-879.
274. Neuberger J, Forman D, Doll R, Williams R. 1986. Oral contraceptives and hepatocellular carcinoma. Br Med J 292:1355-1357.
275. Nicholson WJ, Hammond EC, Seidman H, Selikoff IJ. 1975. Mortality experience of a cohort of vinyl chloride-polyvinyl chloride workers. Ann NY Acad Sci 246:225-230.
276. Niederau C, Fischer R, Purschel A, Stremmel W, Saussinger D, Strohmeyer G. 1996. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 110:1107-1119.
277. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. 1985. Survival and cause of death in cirrhotic and in non-cirrhotic patients with primary hemochromatosis. New Engl J Med 131:1256-1261.
278. Niederau C, Lange S, Heintges T, et al. 1998. Prognosis of chronic hepatitis C: Results of a large prospective cohort study. Hepatology 28:1687-1695.
279. Nishiguchi S, Shiomi S, Nakatani S, et al. 2001. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 357:196-197.
280. Nyberg U, Nilsson B, Travis LB, Holm L-E, Hall P. 2002. Cancer incidence among Swedish patients exposed to radioactive Thorotrast: A forty-year follow-up survey. Radiat Res 157:419-425.
281. Oberti F, Valsesia E, Pilette C, et al. 1997. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 113:1609-1616.
282. Okada K, Kamiyama I, Inomata M, Imai M, Miyakawa Y. 1976. e Antigen and anti-e in the serum of a symptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B to their infants. N Engl J Med 294:746-749.
283. Okuda K, Fujimoto I, Hanai A, Urano Y. 1987. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 47:4967-4972.
284. Okuda K, Nakanuma Y, Miyazaki M. 2002. Cholangiocarcinoma: Recent progress. Part I: epidemiology and etiology. J Gastroenterol Hepatol 17:1049-1055.
285. Okuno M, Kojima S, Akita K, et al. 2002. Retinoids in liver fibrosis and cancer. Front Biosci 7:d204-d218.
286. Olubuyide IO, Bamgboye EA. 1990. A case-controlled study of the current role of cigarette smoking and alcohol consumption in primary liver cell carcinoma in Nigeria. Afr J Med Sci 19:191-194.
287. Omer RE, Verhoef L, Van't Veer P, et al. 2001. Peanut butter intake, GSTM1 genotype and hepatocellular carcinoma: A case-control study in Sudan. Cancer Causes Control 12:23-32.
288. Oshima A, Tsukuma H, Hiyama T, Fujimoto I, Yamano H, Tanaka M. 1984. Follow-up study of HBsAg-positive blood donors with special reference to effect of drinking and smoking on development of liver cancer. Int J Cancer 34:775-779.
289. Ott MG, Langner RR, Holder BH. 1975. Vinyl chloride exposure in a controlled industrial environment. Arch Environ Health 30:333-339.
290. Overly WL, Dankoff JA, Wang BK, Singh UD. 1984. Androgens and hepatocellular carcinoma in an athlete (letter). Ann Intern Med 100:158-159.
291. Ozturk M. 1991. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 338:1356-1359.
292. Palmer JR, Rosenberg L, Kaufman DW, Warshauer ME, Stolley P, Shapiro S. 1989. Oral contraceptive use and liver cancer. Am J Epidemiol 130:878-882.
293. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. 2001. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: A meta-analysis. Aliment Pharmacol Ther 15:689-698.
294. Parkin DM. 2001b. Global cancer statistics in the year 2000. Lancet Oncol 2:533-543.
295. Parkin DM, Bray FI, Devesa SS. 2001a. Cancer burden in the year 2000. The global picture. Eur J Cancer 37: Suppl 8:S4-S66.
296. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, eds. 1997. Cancer Incidence in Five Continents, Vol. VII. IARC Scientific Publications No. 143. Lyon: IARCPress.
297. Pascale RM, Simile MM, De Miglio MR, et al. 1995. Chemoprevention by S-adenosyl-L-methionine of rat liver carcinogenesis initiated by 1,2-dimethylhydrazine and promoted by orotic acid. Carcinogenesis 16:427-430.
298. Patel T. 2002. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2:10. Epub 2002 May 03.
299. Perlmutter DH. 1998. Alpha-1-antitrypsin deficiency. Semin Liver Dis 18:217-225.
300. Persson I, Yuen J, Bergkvist L, Schairer C. 1996. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int J Cancer 67:327-332.
301. Petrides AS, Defronzo RA. 1989. Glucose and insulin metabolism in cirrhosis. J Hepatol 8:107-114.
302. Piperno A, Sampietro M, D'Alba R, et al. 1996. Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 16:248-254.
303. Pointon JJ, Wallace D, Merryweather-Clarke AT, Robson KJ. 2000. Uncommon mutations and polymorphisms in the hemochromatosis gene. Genet Test 4:151-161.
304. Polizos A, Kelekis N, Sinani C, Patsiaoura K, Papadamou G, Dalekos GN. 2003. Advanced intrahepatic cholangiocarcinomas in hepatitis C virus-related decompensated cirrhosis: Case-report and review of the literature. Eur J Gastroenterol Hepatol 15:331-334.
305. Poonawala A, Nair SP, Thuluvath PJ. 2000. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study. Hepatology 32:689-692.
306. Popper H, Roth RL, Purcell RH, et al. 1987. Hepatocarcinogenicity of the woodchuck hepatitis virus. Proc Natl Acad Sci USA 84:866-870.
307. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. 1990. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology 11:74-80.
308. Powell LW, Jazwinska EC, Halliday JW. 1994. Primary iron overload. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. Iron Metabolism in Health and Disease. London: WB Saunders, pp. 228-270.
309. Poynard T, Bedossa P, Opolon P for the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. 1997. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349:825-832.
310. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. 1973. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646-649.
311. Pyong SJ, Tsukuma H, Hiyama T. 1994. Case-control study of hepatocellular carcinoma among Koreans living in Osaka, Japan. Jpn J Cancer Res 85:674-679.
312. Qian GS, Ross RK, Yu MC, et al. 1994. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 3:3-10.
313. Qin G, Gopalan-Kriczky P, Su J, Ning Y, Lotlikar PD. 1997. Inhibition of aflatoxin B1-induced initiation of hepatocarcinogenesis in the rat by green tea. Cancer Lett 112:149-154.
314. Qin G, Ning Y, Lotlikar PD. 2000. Chemoprevention of aflatoxin B1-initiated and carbon tetrachloride-promoted hepatocarcinogenesis in the rat by green tea. Nutr Cancer 38:215-222.
315. Qu D, Teckman JH, Perlmutter DH. 1997. Metabolic liver diseases. Review: alpha 1-antitrypsin deficiency associated liver disease. J Gastroenterol Hepatol 12:404-416.
316. Regelson W. 1968. Hemangioendothelial sarcoma of the liver from chronic arsenic intoxication by Fowler's solution. Cancer 21:514-522.
317. Rennke H, Prat G, Etcheverry R, Katz R, Donoso S. 1971. Hemangioendotelioma maligno del higado y arsenicismo cronico. Rev Med Chile 99:664-668.
318. Rezvani I. 2000. Defects in metabolism of amino acids. In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson Textbook of Pediatrics. Philadelphia: WB Saunders, pp. 345-377.
319. Ries LAG, Eisner MP, Kosary CL, et al., eds. 2003. SEER Cancer statistics review, 1975-2000. National Cancer Institute, Bethesda, MD. Available at:
320. Roberts AG, Whatley SD, Morgan RR, Worwood M, Elder GH. 1997. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 349:321-323.
321. Roetto A, Totaro A, Cazzola M, et al. 1999. Juvenile hemochromatosis locus maps to chromosome lq. Am J Hum Genet 64:1388-1393.
322. Rooks JB, Ory HW, Ishak KG, et al. 1979. Epidemiology of hepatocellular adenoma. JAMA 242:644-648.
323. Rosen CB, Najorney DM, Wiesner RH, Coffey RJ Jr., Larusso NF. 1991. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 213:21-25.
324. Ross RK, Yuan JM, Yu MC, et al. 1992. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 339:943-946.
325. Roth F. 1957. The sequelae of chronic arsenic poisoning in Moselle vintners. German Med Month 2:172-175.
326. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. 1997. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: A French survey of 6,664 patients. Hepatology 26:485-490.
327. Sampietro M, Piperno A, Lupica L. 1998. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology 27:181-184.
328. Sasaki A. 1994. Mortality and causes of death in patients with diabetes mellitus in Japan. Diabetes Res Clin Pract 24 Suppl:S299-306.
329. Sasaki A, Uehara M, Horiuchi N, Hasegawa K, Shimizu T. 1996. A 15 year follow-up study of patients with non-insulin dependent diabetes mellitus (NIDDM) in Osaka, Japan. Long-term prognosis and causes of death. Diabetes Res Clin Pract 34:47-55.
330. Sauvaget C, Nagano J, Hayashi M, Spencer E, Shimizu Y, Allen N. 2003. Vegetables and fruit intake and cancer mortality in the Hiroshima/Nagasaki Life Span Study. Br J Cancer 88:689-694.
331. Schafer DF, Sorrell MF. 1999. Hepatocellular carcinoma. Lancet 353:1253-1257.
332. Schottenfeld D. 1979. Alcohol in the etiology of cancer. Cancer 43:1962-1966.
333. Seef LB, Buskell-Bales Z, Wright EC, et al. 1992. Long term mortality after transfusion associated non-A, non-B hepatitis. N Engl J Med 327:1906-1911.
334. Seef LB, Hollinger FB, Alter HJ, et al. 2001. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology 33:455-463.
335. Seef LB, Miller RN, Rabkin CS, et al. 2000. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Int Med 132:105-111.
336. Seeger C, Mason WS. 2000. Hepatitis B virus biology. Microbial Mol Biol Rev 64:51-68.
337. SEER (Surveillance, Epidemiology, and End Results) Program. 2003 () SEER*Stat Database: Incidence-SEER 9 Regs, Nov 2002 Sub (1973-2000), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2003, based on the November 2002 submission.
338. Seitz HK, Poschl G, Simanowski UA. Alcohol and cancer. 1998. Recent Development Alcoholism 14:67-95.
339. Shafritz DA, Shouval D, Sherman HI, et al. 1981. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. N Engl J Med 305:1067-1073.
340. Shibata A, Fukuda K, Nishiyori A, Ogimoto I, Sakata R, Tanikawa K. 1998. A case-control study on male hepatocellular carcinoma based on hospital and community controls. J Epidemiol 8:1-5.
341. Shibata A, Hirohata T, Toshima H, Tashiro H. 1986. The role of drinking and cigarette smoking in the excess deaths from liver cancer. Jpn J Cancer Res 77:287-295.
342. Shimada M, Hashimoto E, Taniai M, et al. 2002. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 37:154-160.
343. Shin HR, Lee CU, Park HJ, et al. 1996. Hepatitis B and C virus, clonorchis sinensis for the risk of liver cancer: A casecontrol study in Pusan, Korea. Int J Epidemiol 25:933-940.
344. Silvestri L, Lonzogni L, De Silvestri A, et al. 2003. CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer. Int J Cancer 104:310-317.
345. Simon M, Bourel M, Fauchet R, Genetet B. 1976. Association of HLA-A3 and HLA-B14 antigens with idiopathic hemochromatosis. Gut 17:332-334.
346. Sithithaworn P, Haswell-Elkins MR, Mairiang P, et al. 1994. Parasite-associated morbidity: Liver fluke infection and bile duct cancer in northeast Thailand. Int J Parasitol 24:833-843.
347. Snyder PJ. 2001. Androgens. In: Goodman & Gilman's The Pharmalogical Basis of Therapeutics. Hardman JG, Limbird LE, eds. New York: McGraw-Hill, pp. 1635-1648.
348. Soe KL, Soe M, Gluud CN. 1992. Liver pathology associated with the use of anabolic-androgenic steroids. Liver 12:73-79.
349. Sorensen HT, Friis S, Olsen JH, et al. 1998. Risk of liver and other types of cancer in patients with cirrhosis: A nationwide cohort study in Denmark. Hepatology 28:921-925.
350. Sorensen HT, Mellemkjaer L, Jepsen P, et al. 2003. Risk of cancer in patients hospitalized with fatty liver. J Clin Gastroenterol 36:356-359.
351. Srinivasan R, Dean HA. 1997. Thorotrast and the liver-revisited. J Toxicol Clin Toxicol 35:199-202.
352. Srivatanakul P. 2001. Epidemiology of liver cancer in Thailand. Asian Pac J Cancer Prev 2:117-121.
353. Srivatanakul P, Parkin DM, Khlat M, et al. 1991. Liver cancer in Thailand. II. A case-control study of hepatocellular carcinoma. Int J Cancer 48:329-332.
354. Stanford JL, Thomas DB, WHO Collaborative Study of Neoplasia and Steroid Contraceptives. 1992. Reproductive factors in the etiology of hepatocellular carcinoma. Cancer Causes Control 3:37-42.
355. Stemhagen A, Slade J, Altman R, et al. 1983. Occupational risk factors and liver cancer: A retrospective case-control study of primary liver cancer in New Jersey. Am J Epidemiol 117:443-454.
356. Stevens CE, Beasley RP, Tsui J, Lee WC. 1975. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 292:771-774.
357. Stevens RG, Beasley RP, Blumberg BS. 1986. Iron-binding proteins and risk of cancer in Taiwan. J Natl Cancer Inst 76:605-610.
358. Stocker JT, Ishak KG. 1987. Hepatoblastoma. In: Okuda K, Ishak KG, eds. Neoplastic Diseases of the Liver. Berlin: Springer-Verlag, pp. 127-136.
359. Strachan AS. 1929. Haemosiderosis and haemochromatosis in South African natives with a comment on the etiology of haemochromatosis. MD Thesis: University of Glasgow, Glasgow, Scotland.
360. Struben VM, Hespenheide EE, Caldwell SH. 2000. Nonalcoholic steatohepatitis and cryptogeneic cirrhosis within kindreds. Am J Med 108:9-13.
361. Summers J, Jilbert AR, Yang W, et al. 2003. Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc Natl Acad Sci USA 100:11652-11659.
362. Summers J, Smolec JM, Snyder R. 1978. A virus similar to hepatitis B associated with hepatitis and hepatoma in woodchucks. Proc Natl Acad Sci USA 75:4533-4537.
363. Sun C-A, Wang L-Y, Chen C-J, et al. 2001. Genetic polymorphisms of glutathione-s-transferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: A nested case-control study in Taiwan. Carcinogenesis 22:1289-1294.
364. Suriawinata A, Ivanov K, Ben Haim M, Schwartz ME. 2000. A 67-year-old man with hepatitis C virus infection and a liver tumor. Semin Liver Dis 20:227-231.
365. Sveger T. 1976. Liver disease in a1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 294:1316-1321.
366. Tabershaw IR, Gaffey WR. 1974. Mortality study of workers in the manufacture of vinyl chloride and its polymers. J Occup Med 16:509-518.
367. Tagger A, Donato F, Ribero ML, et al. 1999. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: The role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 81:695-699.
368. Takaishi H, Kitamoto M, Takahashi S, et al. 2000. Precancerous hepatic nodules had significant levels of telomerase activity determined by sensitive quantitation using a hybridization protection assay. Cancer 88:312-317.
369. Takemura Y, Kikuchi S, Inaba Y. 1998. Epidemiologic study of the relationship between schistosomiasis due to Schistosoma japonicum and liver cancer/cirrhosis. Am J Trop Med Hyg 59:551-556.
370. Takeshita T, Yang X, Inoue Y, Sato S, Morimoto K. 2000. Relationship between alcohol drinking, ADH2 and ALDH2 genotypes, and risk for hepatocellular carcinoma in Japanese. Cancer Lett 149:69-76.
371. Tan AY, Lao CH, Lee YS. 1977. Hepatitis B antigen in the liver cells in cirrhosis and hepatocellular carcinoma. Pathology 9:57-64.
372. Tanaka K, Hirohata T, Fukuda K, et al. 1995. Risk factors for hepatocellular carcinoma among Japanese women. Cancer Causes Control 6:91-98.
373. Tanaka K, Hirohata T, Takashita S. 1988. Blood transfusion, alcohol consumption, and cigarette smoking in causation of hepatocellular carcinoma: A case-control study in Fukuoka, Japan. Jpn J Cancer Res (Gann) 79:1075-1082.
374. Tanaka K, Hirohata T, Takashita, et al. 1992. Hepatitis B virus, cigarette smoking and alcohol consumption in the development of hepatocellular carcinoma: A case-control study in Fukuoka, Japan. Int J Cancer 51:509-514.
375. Tanaka T, Imamura A, Hayashi S, et al. 1998a. Minute mixed hepatoma with two components: Hepatocellular and cholangiocarcinoma, which developed on liver cirrhosis with HCV. Hepatogastroenterology 45:220-223.
376. Tanaka K, Sakai H, Hashizume M, et al. 1998b. A long-term follow-up study on risk factors for hepatocellular carcinoma among Japanese patients with liver cirrhosis. Jpn J Cancer Res 89:1241-1250.
377. Tavani A, Negri E, Parazzini F, Franceschi S, La Vecchia C. 1993. Female hormone utilisation and risk of hepatocellular carcinoma. Br J Cancer 67:635-637.
378. Taylor-Robinson SD, Toledano MB, Arora S, et al. 2001. Increase in mortality rates for intrahepatic cholangiocarcinomas in England and Wales, 1968-1998. Gut 48:816-820.
379. The UK Haemochromatosis Consortium. 1997. A simple genetic test identifies 90% of UK patients with haemochromatosis. Gut 41:841-844.
380. Thio CL. 2003. Hepatitis B in the human immunodeficiency virus-infected patient: Epidemiology, natural history, and treatment. Semin Liver Dis 23:125-136.
381. Thio CL, Seaberg EC, Skolasky, et al. 2002. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360:1921-1926.
382. Thorgeirsson SS, Grisham JW. 2002. Molecular pathogenesis of human hepatocellular carcinoma. Nature Genetics 31:339-346.
383. Tiemersma EW, Omer RE, Bunschoten A, et al. 2001. Role of genetic polymorphism of glutathione-S-transferase T1 and microsomal epoxide hydrolase in aflatoxin-associated hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 10:785-791.
384. Tomimatsu M, Ishiguro N, Taniai M, et al. 1993. Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma). Cancer 72:683-688.
385. Tong MJ, El-Farra NS, Reikes AR, Co RL. 1995. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 332:1463-1466.
386. Tornillo L, Carafa V, Sauter G, et al. 2002. Chromosomal alterations in hepatocellular nodules by comparative genomic hybridization: High-grade dysplastic nodules represent early stages of hepatocellular carcinoma. Lab Invest 82:547-553.
387. Toshkov I, Hacker HJ, Roggendorf M, Bannasch PJ. 1990. Phenotypic patterns of preneoplastic and neoplastic hepatic lesions in woodchucks infected with woodchuck hepatitis virus. Cancer Res Clin Oncol 116:581-590.
388. Toyoda H, Kumada T, Nakano S, et al. 2001. Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C. Oncology 61:134-142.
389. Travis LB, Kathren RL, Boice JD. 1992. Cancer risk following exposure to Thorotrast: Overview in relation to a case report. Health Phys 63:89-97.
390. Travis LB, Land CE, Andersson M, et al. 2001. Mortality after cerebral angiography with or without radioactive Thorotrast: An international cohort of 3,143 two-year survivors. Radiat Res 156:136-150.
391. Tremolada F, Casarin C, Alberti A, et al. 1992. Long-term follow-up of nonA, non-B (type C) post-transfusion hepatitis. J Hepatol 16:273-281.
392. Trichopoulos D, Day N, Kaklamani E, et al. 1987. Hepatitis B virus, tobacco smoking and ethanol consumption in the etiology of hepatocellular carcinoma. Int J Cancer 39:45-49.
393. Trichopoulos D, MacMahon B, Sparros L, et al. 1980. Smoking and hepatitis B-negative primary hepatocellular carcinoma. J Natl Cancer Inst 65:111-114.
394. Tsuda T, Babazono A, Yamamoto E, et al. 1995. Ingested arsenic and internal cancer: A historical cohort study followed for 33 years. Am J Epidemiol 141:198-209.
395. Tsukazaki N, Watanabe M, Irifune H. 1998. Porphyria cutanea tarda and hepatitis C virus infection. Br J Dermatol 138:1015-1017.
396. Tsukuma H, Hiyama T, Oshima A, et al. 1990. A case-control study of hepatocellular carcinoma in Osaka, Japan. Int J Cancer 45:231-236.
397. Tsukuma H, Hiyama T, Tanaka S, et al. 1993. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328:1797-1801.
398. Tu J, Gao R, Zhang D, et al. 1985. Hepatitis B virus and primary liver cancer on Chongming Island, People's Republic of China. Natl Cancer Inst Monogr 69:213-215.
399. Tuyns AJ, Pequignot G. 1984. Greater risk of ascitic cirrhosis in women in relation to alcohol consumption. Int J Epidemiol 13:53-57.
400. Tzonou A, Trichopoulos D, Kaklamani E, et al. 1991. Epidemiologic assessment of interactions of hepatitis-C virus with seromarkers of hepatitis-B and -D viruses, cirrhosis and tobacco smoking in hepatocellular carcinoma. Int J Cancer 49:377-380.
401. Tzonou A, Zavitsanos X, Hsieh CC, Trichopoulos D. 1992. Liveborn children and risk of hepatocellular carcinoma. Cancer Causes Control 3:171-174.
402. Vall Mayans M, Calvet X, Bruix J, et al. 1990. Risk factors for hepatocellular carcinoma in Catalonia, Spain. Int J Cancer 46:378-381.
403. Van Kaick G, Dalheimer A, Hornik S, et al. 1999. The German Thorotrast study: Recent results and assessment of risks. Radiat Res 152:S64-S71.
404. Velazquez RF, Rodriguez M, Navascues CA, et al. 2003. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 37:520-527.
405. Vessey CJ, de la Hall PM. 2001. Hepatic stem cells: a review. Pathology 33:130-141.
406. Wade N. 1972. Anabolic steroids (news). Science 176:1399-1403.
407. Wahib AA, Masoud AA, Halem AA, et al. 1998. Cell mediated immune response in chronic liver diseases: Schistosomal, viral and neoplastic. J Egypt Soc Parasitol 28:929-939.
408. Ward E, Boffetta P, Andersen A, et al. 2001. Update of the follow-up of mortality and cancer incidence among European workers employed in the vinyl chloride industry. Epidemiology 12:710-718.
409. Watanapa P, Watanapa WB. 2002. Liver fluke-associated cholangiocarcinoma. Br J Surg 89:962-970.
410. Weiderpass E, Gridley G, Nyren O, Pennello G, Landstrom AS, Ekbom A. 2001. Cause-specific mortality in a cohort of patients with diabetes mellitus: A population-based study in Sweden. J Clin Epidemiol 54:802-809.
411. WHO. 2000. Hepatitis C Fact Sheet. WHO fact sheet no. 164. (internet).
412. WHO. 2002. Global burden of disease. In: The World Health Report 2002, Reducing risks, promoting healthy life, Geneva.
413. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. 1989. Combined oral contraceptives and liver cancer. Int J Cancer 43:254-259.
414. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. 1991. Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer. Int J Cancer 49:182-185.
415. Wideroff L, Gridley G, Mellemkjaer L, et al. 1997. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89:1360-1365.
416. Wiese M, Berr F, Lafrenz M, et al. 2000. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: A 20-year multicenter study. Hepatology 32:91-96.
417. Wong NA, Rae F, Bathgate A, Smith CA, Harrison DJ. 2000. Polymorphisms of the gene for microsomal epoxide hydrolase and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a Caucasian population. Toxicol Lett 115:17-22.
418. Wong RH, Chen PC, Du CL, Wang JD, Cheng TJ. 2002. An increased standardized mortality ratio for liver cancer among polyvinyl chloride workers in Taiwan. Occup Environ Med 59:405-409.
419. World Cancer Research Fund, American Institute for Cancer Research. 1997. Liver. In Food, Nutrition and the Prevention of Cancer: A global perspective. Washington, D.C., American Institute for Cancer Research, pp. 202-214.
420. Wright TL. 2002. Treatment of patients with hepatitis C and cirrhosis. Hepatology 36:S185-194.
421. Wu MM, Kuo TL, Hwang YH, Chen CJ. 1989. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol 130:1123-1132.
422. Yamamoto M, Takasaki K, Nakano M, Saito A. 1998. Minute nodular intrahepatic cholangiocarcinoma. Cancer 82:2145-2149.
423. Yang BH, Tang ZY. 1985. Hepatitis b virus and hepatocellular carcinoma-clinical and serological aspects. In: Tang ZY, ed. Sub-Clinical Hepatocellular Carcinoma. Berlin: Springer-Verlag, pp. 212-217.
424. Yano M, Kumada H, Kage M, et al. 1996. The long-term pathological evolution of chronic hepatitis C. Hepatology 23:1334-1340.
425. Ye B, Shen J, Xu Y. 1994. Etiologic study on the relationship between HB V, HCV and HCC. Zhonghua Liu Xing Bing Xue Za Zhi 15:131-134.
426. Yee TT, Griffioen A, Sabin CA, Dusheiko G, Lee CA. 2000. The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Semin Liver Dis 23:149-166.
427. Yeh SH, Chang CF, Shau WY, et al. 2002. Dominance of functional androgen receptor allele with longer CAG repeat in hepatitis B virus-related female hepatocarcinogenesis. Cancer Res 62:4346-4351.
428. Yin F, Chen B. 1998. Detection of hepatitis C virus RNA sequences in hepatic portal cholangiocarcinoma tissue by reverse transcription polymerase chain reaction. Chin Med J 111:1068-1070.
429. Yoshida H, Shiratori Y, Moriyama M, et al. 1999. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 131:174-181.
430. Yu H, Harris R, Kabat G, et al. 1988a. Cigarette smoking, alcohol consumption and primary liver cancer: A casecontrol study in the U.S.A. Int J Cancer 42:325-328.
431. Yu MC, Mack T, Hanish R, et al. 1983. Hepatitis, alcohol consumption, cigarette smoking and hepatocellular carcinoma in Los Angeles. Cancer Res 42:6077-6079.
432. Yu MC, Tong MJ, Govindarajan S, Henderson BE. 1991a. Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California. J Natl Cancer Inst 83:1820-1826.
433. Yu MW, Chen CJ. 1993. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res 53:790-794.
434. Yu MW, Cheng SW, Lin MW, et al. 2000b. Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst 92:2023-2028.
435. Yu MW, Chiu YH, Chiang YC, et al. 1999b. Plasma carotenoids, glutathione s-transferase M1 and T1 genetic polymorphisms, and risk of hepatocellular carcinoma: Independent and interactive effects. Am J Epidemiol 149:621-629.
436. Yu MW, Chiu YH, Yang SY, et al. 1999c. Cytochrome p4501A1 genetic polymorphisms and risk of hepatocellular carcinoma among chronic hepatitis B carriers. Br J Cancer 80:598-603.
437. Yu MW, Gladek-Yarborough A, Chiamprasert S, Santella RM, Liaw YF, Chen CJ. 1995. Cytochrome p450 2E1 and glutathione s-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology 109:1266-1273.
438. Yu MW, Horng IS, Hsu KH, Chiang YC, Liaw YF, Chen CJ. 1999a. Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis infection. Am J Epidemiol 150:367-374.
439. Yu MW, Hsu FC, Sheen IS, et al. 1997a. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 145:1039-1047.
440. Yu MW, Pai CI, Yang SY, et al. 2000a. Role of N-acetyltransferase polymorphisms in hepatitis B related hepatocellular carcinoma: Impact of smoking on risk. Gut 47:703-709.
441. Yu MW, Yang YC, Yang SY, et al. 2001. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: A nested case-control study among men. J Natl Cancer Inst 93:1644-1651.
442. Yu SY, Chu YJ, Li WG. 1988b. Selenium chemoprevention of liver cancer in animals and possible human applications. Biol Trace Elem Res 15:231-241.
443. Yu SY, Zhu YJ, Li WG. 1997b. Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biol Trace Elem Res 56:117-124.
444. Yu SY, Zhu YJ, Li WG, et al. 1991b. A preliminary report on the intervention trials of primary liver cancer in high-risk populations with nutritional supplementation of selenium in China. Biol Trace Elem Res 29:289-294.
445. Yuan JM, Ross, RK, Stanczyk FZ, et al. 1995. A cohort study of serum testosterone and hepatocellular carcinoma in Shanghai, China. Int J Cancer 63:491-493.
446. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. 2001. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 34:139-145.
447. Zen Y, Katayanagi K, Tsuneyama K, Harada K, Araki I, Nakanuma Y. 2001. Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 51:127-131.
448. Zhou H, Ortiz-Pallardo ME, Ko Y, Fischer H-P. 2000. Is heterozygous alpha1-antitrysin deficiency type PiZ a risk factor for primary liver cancer? Cancer 88:2668-2676.